Sector analysis published in September 2025 describes attackers pursuing drug formulations and research data alongside patient information in the pharmaceutical sector.
The Corpus Has Recorded This Asymmetry Five Times
Manufacturing process data at 25-1204. Litigation strategy at 25-0916. Network documentation at 25-0611 and 25-1128. Accounting records and legal agreements at 25-1124b. Now drug formulations.
In every case the material is more valuable to the organisation than the personal data it holds alongside it, and in every case no notification obligation attaches because no individual is identifiable in it.
Pharmaceutical IP Is The Extreme Case
A formulation and its supporting data represent the entire return on a development programme measured in years and billions. Losing it to a competitor or a state-linked actor is not a compliance event; it is a transfer of the company’s reason for existing.
The corpus filed state-linked collection targeting manufacturing at 25-1213 and 25-0731. Pharmaceutical research is a standing target for exactly that kind of activity, and it produces no filing anywhere.
Which Distorts What The Sector Is Measured On
Pharmaceutical breach coverage — including this corpus — concentrates on patient and trial data, because that is what generates notifications, at 25-0912b and 25-0630.
If the more consequential loss is research material, the visible record measures the lesser harm. It is the same inversion this desk filed at 25-1204 for manufacturing: on every register in this corpus, the incident that mattered most did not happen.
Graded medium: this is sector commentary rather than incident data, and the corpus has no case where research IP loss was confirmed.
Built on published sector analysis, listed below, read against the intellectual property files in this database. No specific IP loss is established. Corrections: corrections@forensicpost.com.
- Attackers are coming for drug formulas and patient dataHelp Net Security
- Cybersecurity in pharma: threats in 2025PharmaNow